Stayble Therapeutics

@Stayble

Stayble is a clinical-stage pharmaceutical company developing the STA363 injection treatment for degenerative disc disease and chronic disc herniation.

Göteborg, Sverige staybletherapeutics.se Joined June 2014

40 Following 130 Followers 63 Posts

Latest posts 5

Stayble Therapeutics @Stayble Dec 18, 2023

BioStock contacted CEO Andreas Gerward who shared his thoughts and provided further details about the recent findings and what they mean for the future of herniated disc treatments.

Link: biostock.se/en/2023/12/sta…

#discherniation #backpain

Stayble Therapeutics @Stayble Dec 12, 2023

New insights from Stayble!

Data from Stayble's Phase IIb study strengthens the foundation of our treatment for herniated discs.

Discover more in the full press release: staybletherapeutics.com/cision-feed/st…

#herniateddiscs #backpain

Stayble Therapeutics @Stayble Nov 22, 2023

Stayble Therapeutics shifts focus to phase Ib study in disc herniation!

Following recent events, our CEO, Andreas Gerward, met with BioStock and shared his insights about the future plans for Stayble.

Link: biostock.se/en/2023/11/sta…

#backpain #clinicaltrial #herniateddisc

Stayble Therapeutics @Stayble Nov 15, 2023

The interim report for the third quarter is now available!

Stayble Therapeutics has published its interim report for the third quarter of 2023.

Explore the full report by following the link: staybletherapeutics.com/wp-content/upl…

Stayble Therapeutics @Stayble Nov 3, 2023

Stayble is on track to present top-line data from the Phase IIb study of STA363. The anticipated results are set to be shared within the next month, with a target of November or early December.

lnkd.in/eY9Yianm

#backpain #degenerativediscdisease #healthcare